Astellas furthers oncology ambitions with $765 million Medivation deal
28 October 2009
Ian Haydock
Astellas has acquired global rights to
Medivation's investigational prostate cancer drug MDV3100, in an alliance worth up to $765 million in up-front and milestone payments to the US firm.
The two companies will jointly commercialise the oral anti-androgen small molecule in the US, where they...
Please Login to read the full article.
28 October 2009
Ian Haydock
The two companies will jointly commercialise the oral anti-androgen small molecule in the US, where they...
Please Login to read the full article.
RELATED CONTENT
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
